Atara Biotherapeutics, Inc.
Pagina dedicata companiei Atara Biotherapeutics, Inc. listata cu simbolul US.ATRA
Descriere companie[edit | ]
Atara Biotherapeutics, Inc. (www.atarabio.com) is engaged in developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers and autoimmune disease. The Company’s pipeline products include Tab-cel and ATA188, as well as ATA2271, ATA3271 and ATA3219 under CAR T Programs. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. The Company’s ATA188 is a T-cell immunotherapy targeting EBV antigens for the treatment of multiple sclerosis. Its ATA2271 is an autologous chimeric antigen receptors (CAR) T immunotherapy targeting solid tumors expressing the tumor antigen mesothelin.
Grafic actiuni companie[edit | ]